Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September 30, 2020
Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020
All proposed resolutions approved with large majority
HALLE (SAALE) / MUNICH, Germany, 01 October 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today that its shareholders approved all resolutions proposed by the Company’s management and Supervisory Board at the Company’s Annual General Meeting which took place on Wednesday, September 30, 2020, including:
- The discharge of the members of the management and Supervisory Boards with respect to the 2019 financial year
- The appointment of KPMG AG Wirtschaftsprüfungsgesellschaft as auditor for the 2020 financial year
- Elections to the Supervisory Board
- Resolution on the Remuneration of the Supervisory Board
- Resolution on the Creation of a Stock Option Program 2020, the Creation of a Conditional Capital 2020/I as well as the Corresponding Amendments to the Articles of Association
- Resolution on the Creation of an Authorized Capital 2020 Cancelling the Conditional Capital 2019, as well as the Corresponding Amendment to the Articles of Association
- Transfer of the Company’s Official Seat and Conversion into and Adoption of Articles of Association of a Public Company under the Laws of the Netherlands
47.72 % of the voting shares were represented at the 2020 Vivoryon Therapeutics AG AGM.
All resolutions proposed by the Company’s management and Supervisory Board were approved at the meeting with a large majority. The voting results can be found on the Company’s website:
www.vivoryon.com/investors-news/ordinary-general-meeting-of-shareholders-2020
Objection was declared for a total of less than 2% of the total outstanding voting rights and recorded in the minutes of the Annual General Meeting. Therefore, the Management Board is instructed to complete the transfer of the registered office to the Netherlands, the conversion and the related amendment of the Articles of Association.
Dr. Ulrich Dauer, Chief Executive Officer of Vivoryon Therapeutics AG, said: “We would like to take this opportunity to thank all of our employees, advisors and consultants, as well as the members of the Supervisory Board, partners and shareholders for their commitment, trust and support.”
###
For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
Email: contact@vivoryon.com
Trophic Communications
Gretchen Schweitzer / Joanne Tudorica
Tel: +49 172 861 8540 / +49 176 2103 7191
Email: vivoryon@trophic.eu
About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon’s scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, varoglutamstat (PQ912), in Alzheimer’s disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury.
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.